Marleen Kok, MD PhD, NKI
@marleenkok.bsky.social
Breast Oncologist and translational researcher @nki, Immunotherapy and immune cell lover, Mother, 🍀🌿
More than proud to be working @nkinl.bsky.social under the great leadership of @thijnbrummel.bsky.social. His achievements in the field of fundamental sciences ✍️🔬are truly amazing! Congrats Thijn🥳
Proud! 💙 Our scientific director Thijn Brummelkamp receives the Spinoza Prize, a prize for scientists who belong to the best researchers worldwide. A wonderful recognition for his groundbreaking research.
Congrats Thijn! 🎉 @thijnbrummel.bsky.social
Full article ➡️ bit.ly/40p4KnK
Congrats Thijn! 🎉 @thijnbrummel.bsky.social
Full article ➡️ bit.ly/40p4KnK
July 3, 2025 at 8:59 PM
More than proud to be working @nkinl.bsky.social under the great leadership of @thijnbrummel.bsky.social. His achievements in the field of fundamental sciences ✍️🔬are truly amazing! Congrats Thijn🥳
Reposted by Marleen Kok, MD PhD, NKI
#ESMOBreast25: Low baseline tumour infiltrating lymphocytes #TILs and nodal involvement may predict #BreastCancer patients with poor prognosis despite pathological complete response to neoadjuvant chemotherapy.
#ESMODailyReporter has more
🔗 buff.ly/YmxaCJ7
#ESMODailyReporter has more
🔗 buff.ly/YmxaCJ7
May 15, 2025 at 1:10 PM
#ESMOBreast25: Low baseline tumour infiltrating lymphocytes #TILs and nodal involvement may predict #BreastCancer patients with poor prognosis despite pathological complete response to neoadjuvant chemotherapy.
#ESMODailyReporter has more
🔗 buff.ly/YmxaCJ7
#ESMODailyReporter has more
🔗 buff.ly/YmxaCJ7
I just learned a new pathologist joke: “Tumors dont read J Clin Oncol” from Beppe Viale cited by Carsten Denkert. 🧐📔We as researchers oversimplify cancer biology but tumors dont always follow our classifications @myesmo.bsky.social #esmoambassadors #esmobreast25
May 15, 2025 at 2:38 PM
I just learned a new pathologist joke: “Tumors dont read J Clin Oncol” from Beppe Viale cited by Carsten Denkert. 🧐📔We as researchers oversimplify cancer biology but tumors dont always follow our classifications @myesmo.bsky.social #esmoambassadors #esmobreast25
Thanks to Nadia Harbeck 🙏for the following extremely important remarks: 1) we shouldnt aim for using even 2 gene expression test, one expensive test is enough; 2) instead use a dynamic biomarker: Ki67 drop after endocrine tx. @myesmo.bsky.social #esmoambassadors #esmobreast25
May 15, 2025 at 1:06 PM
Thanks to Nadia Harbeck 🙏for the following extremely important remarks: 1) we shouldnt aim for using even 2 gene expression test, one expensive test is enough; 2) instead use a dynamic biomarker: Ki67 drop after endocrine tx. @myesmo.bsky.social #esmoambassadors #esmobreast25
Reposted by Marleen Kok, MD PhD, NKI
An enthusiast and militant talk by @marleenkok.bsky.social at #ESMOBreast25 on the importance of studying biomarkers for immunotherapy in breast cancer, highlighting the KN522 example
#ESMOAmbassadors @myesmo.bsky.social
#ESMOAmbassadors @myesmo.bsky.social
May 14, 2025 at 1:06 PM
An enthusiast and militant talk by @marleenkok.bsky.social at #ESMOBreast25 on the importance of studying biomarkers for immunotherapy in breast cancer, highlighting the KN522 example
#ESMOAmbassadors @myesmo.bsky.social
#ESMOAmbassadors @myesmo.bsky.social
Reposted by Marleen Kok, MD PhD, NKI
The path forward for immunotherapy biomarkers in breast cancer by @marleenkok.bsky.social
#ESMOBreast25 #ESMOAmbassadors @myesmo.bsky.social
#ESMOBreast25 #ESMOAmbassadors @myesmo.bsky.social
May 14, 2025 at 1:22 PM
The path forward for immunotherapy biomarkers in breast cancer by @marleenkok.bsky.social
#ESMOBreast25 #ESMOAmbassadors @myesmo.bsky.social
#ESMOBreast25 #ESMOAmbassadors @myesmo.bsky.social
Really impressive talk by Davide Massa on prognostic value of TILs together with nodal status in patients with TNBC and pCR. Outcome for TIL low and cN+ is not that good. Would additional treatment help? @myesmo.bsky.social #ESMOBreast25 #ESMOAmbassadors
May 15, 2025 at 12:14 PM
Really impressive talk by Davide Massa on prognostic value of TILs together with nodal status in patients with TNBC and pCR. Outcome for TIL low and cN+ is not that good. Would additional treatment help? @myesmo.bsky.social #ESMOBreast25 #ESMOAmbassadors
Do you want to know the most recent ins and outs in breast cancer research and treatment? Follow us 👇for the coolest news from #ESMOBreast25 #BCSM @myesmo.bsky.social
May 12, 2025 at 7:49 AM
Do you want to know the most recent ins and outs in breast cancer research and treatment? Follow us 👇for the coolest news from #ESMOBreast25 #BCSM @myesmo.bsky.social
Reposted by Marleen Kok, MD PhD, NKI
📢 #ESMOFellowship applications are now open!
The Society is committed to supporting #YoungOncologists in developing high-quality #TranslationalResearch and #ClinicalResearch projects.
📅 Apply by: 29 May 2025
🔗 buff.ly/NN5Y1ol
The Society is committed to supporting #YoungOncologists in developing high-quality #TranslationalResearch and #ClinicalResearch projects.
📅 Apply by: 29 May 2025
🔗 buff.ly/NN5Y1ol
April 17, 2025 at 8:55 AM
📢 #ESMOFellowship applications are now open!
The Society is committed to supporting #YoungOncologists in developing high-quality #TranslationalResearch and #ClinicalResearch projects.
📅 Apply by: 29 May 2025
🔗 buff.ly/NN5Y1ol
The Society is committed to supporting #YoungOncologists in developing high-quality #TranslationalResearch and #ClinicalResearch projects.
📅 Apply by: 29 May 2025
🔗 buff.ly/NN5Y1ol
Very very proud of you my friend. You are a star and fantastic scientist!
Very proud to receive this Ammodo Science Award recognition of our lab’s work the past few years @nkinl.bsky.social @oncodeinstitute.bsky.social 🙏🙏. Big up to my fabulous lab peeps, mentors, colleagues, family and friends for all their support. Looking forward to celebrate altogether on May 7th🥳🤩🥰!
Cancer researcher @leilaakkari.bsky.social receives an Ammodo Science Award for fundamental research. These biannual awards encourage outstanding scientists in their groundbreaking, fundamental research ➡️ t.co/SmXpE10QaS
@ammodoscience.bsky.social
Photo Leila Akkari - ©Florian Braakman
@ammodoscience.bsky.social
Photo Leila Akkari - ©Florian Braakman
April 15, 2025 at 11:37 AM
Very very proud of you my friend. You are a star and fantastic scientist!
Please donate!🚵🏽♂️💵💰
Last year we received a huge grant 🤩from KWF to launch the internat OPTImaL trial to avoid chemo for low stage BC with many immune cells!
We strongly feel that we should do something in return for KWF so we will bike 🚵🏽♂️the Alpe d’Huez 💪🏼
www.opgevenisgeenoptie.nl/fundraisers/...
Last year we received a huge grant 🤩from KWF to launch the internat OPTImaL trial to avoid chemo for low stage BC with many immune cells!
We strongly feel that we should do something in return for KWF so we will bike 🚵🏽♂️the Alpe d’Huez 💪🏼
www.opgevenisgeenoptie.nl/fundraisers/...
Marleen Kok
Ik doe mee aan Alpe d’HuZes omdat ik geloof dat wij samen kunnen werken aan een wereld waarin je niet meer doodgaat aan kanker, wil jij mij steunen?
www.opgevenisgeenoptie.nl
April 15, 2025 at 11:30 AM
Please donate!🚵🏽♂️💵💰
Last year we received a huge grant 🤩from KWF to launch the internat OPTImaL trial to avoid chemo for low stage BC with many immune cells!
We strongly feel that we should do something in return for KWF so we will bike 🚵🏽♂️the Alpe d’Huez 💪🏼
www.opgevenisgeenoptie.nl/fundraisers/...
Last year we received a huge grant 🤩from KWF to launch the internat OPTImaL trial to avoid chemo for low stage BC with many immune cells!
We strongly feel that we should do something in return for KWF so we will bike 🚵🏽♂️the Alpe d’Huez 💪🏼
www.opgevenisgeenoptie.nl/fundraisers/...
Very good talk by famous statistician #SGBCC2025
Meredith Regan proposes framework using established criteria for pragmatic clinical trial design, then walks audience thru process using PREPEC. #masterclass #SGBCC2025
March 14, 2025 at 12:40 PM
Very good talk by famous statistician #SGBCC2025
Thanks @drsgraff.bsky.social for your amazing report of -again- an amzing session #SGBCC2025
Marleen Kok @marleenkok.bsky.social had the difficult task of discussing the role of IO in HR+ breast cancer—she focused on ER-low disease, and suggests that we treat as TNBC. #SGBCC2025
March 13, 2025 at 3:30 PM
Thanks @drsgraff.bsky.social for your amazing report of -again- an amzing session #SGBCC2025
With co-director @vkaklamani.bsky.social of @sabcs.bsky.social we have been working on #SABCS25 program! Stay tuned! Super exciting with stellar line-up of speakers. With @heidefordlab.bsky.social @itsnotpink.bsky.social and many other fantastic faculty members #bcsm
March 1, 2025 at 4:04 PM
With co-director @vkaklamani.bsky.social of @sabcs.bsky.social we have been working on #SABCS25 program! Stay tuned! Super exciting with stellar line-up of speakers. With @heidefordlab.bsky.social @itsnotpink.bsky.social and many other fantastic faculty members #bcsm
Good to see your here @renemedema.bsky.social
Times they are a changing. Exit X, happy to join a new community on BlueSky @themaximacenter.bsky.social @hetavl.bsky.social
February 26, 2025 at 12:00 PM
Good to see your here @renemedema.bsky.social
Looking forward to work as senior editor for the @theaacr.bsky.social journal Clin Cancer Res with this 👇 amazing editor-in-chief. Congrats Tim Yap!
Timothy A. Yap, MBBS, PhD, has been appointed editor-in-chief of the AACR journal Clinical Cancer Research. Dr. Yap is co-director for the AACR/ASCO Methods in Clinical Cancer Research Workshop and a past cochair of the AACR Annual Meeting Clinical Trials Committee. www.aacr.org/about-the-aa...
February 25, 2025 at 10:43 PM
Looking forward to work as senior editor for the @theaacr.bsky.social journal Clin Cancer Res with this 👇 amazing editor-in-chief. Congrats Tim Yap!
Bioinformatician in Breast Cancer Immunology | Netherlands Cancer Institute
www.nki.nl
February 17, 2025 at 9:04 AM
Important editorial in the @thelancet.bsky.social Wrong decisions endanger Health care in the US and worldwide, especially for people who need it the most! Lets unit and speak up!📣 www.thelancet.com/journals/lan...
American chaos: standing up for health and medicine
Withdrawal from WHO and the Paris Agreements. USAID shuttered and aid halted, ceasing
health programmes globally. A freeze on US$3 trillion worth of federal grants and
loans, jeopardising the function...
www.thelancet.com
February 9, 2025 at 7:27 AM
Important editorial in the @thelancet.bsky.social Wrong decisions endanger Health care in the US and worldwide, especially for people who need it the most! Lets unit and speak up!📣 www.thelancet.com/journals/lan...
Reposted by Marleen Kok, MD PhD, NKI
This will kill science in the US. This is how China wins. Why is this not on the news? Why are people not more upset about this?
grants.nih.gov/grants/guide...
grants.nih.gov/grants/guide...
NOT-OD-25-068: Supplemental Guidance to the 2024 NIH Grants Policy Statement: Indirect Cost Rates
NIH Funding Opportunities and Notices in the NIH Guide for Grants and Contracts: Supplemental Guidance to the 2024 NIH Grants Policy Statement: Indirect Cost Rates NOT-OD-25-068. OD
grants.nih.gov
February 8, 2025 at 1:43 AM
This will kill science in the US. This is how China wins. Why is this not on the news? Why are people not more upset about this?
grants.nih.gov/grants/guide...
grants.nih.gov/grants/guide...
very important (but negative) trial on cdk46i in mTNBC. huge shout-out to @stolaney1.bsky.social and Shom Goel for conducting this trial👍 @oncoalert.bsky.social #bcsm
📢 Just published! A phase II study of #abemaciclib for patients with #retinoblastoma-positive, triple-negative #metastatic breast cancer.
🔓https://pubmed.ncbi.nlm.nih.gov/39908010/
@drtimothyerick.bsky.social @nlinmd.bsky.social
@stolaney1.bsky.social
🔓https://pubmed.ncbi.nlm.nih.gov/39908010/
@drtimothyerick.bsky.social @nlinmd.bsky.social
@stolaney1.bsky.social
February 7, 2025 at 10:00 PM
very important (but negative) trial on cdk46i in mTNBC. huge shout-out to @stolaney1.bsky.social and Shom Goel for conducting this trial👍 @oncoalert.bsky.social #bcsm
Many good things to say on this story @oncoalert.bsky.social @naturemedicine.bsky.social: 1) serious biomarker work from a pharma-sponsored trial👏👏 2) a tumor historically consid cold 🥶can respond to aPD1 🤩3) we need to redefine ER+ disease to enable personalized treatm✍️
summary CM-7FL @oncoalert.bsky.social
@naturemedicine.bsky.social link: rdcu.be/d8Cw4.
Here Nivo ⬆️ pCR rates in high grade HR+ BC. Increasing pCR rates in this subtype is HARD! PD-L1+ & #TIL higher pCR. This study will change how we think about HR+BC- some are immunogenic & need PD-1i with chemo
@naturemedicine.bsky.social link: rdcu.be/d8Cw4.
Here Nivo ⬆️ pCR rates in high grade HR+ BC. Increasing pCR rates in this subtype is HARD! PD-L1+ & #TIL higher pCR. This study will change how we think about HR+BC- some are immunogenic & need PD-1i with chemo
Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial
Nature Medicine - In the CheckMate 7FL trial, neoadjuvant nivolumab and chemotherapy in patients with newly diagnosed, high-risk estrogen receptor-positive breast cancer led to an increased...
rdcu.be
February 7, 2025 at 9:47 AM
Many good things to say on this story @oncoalert.bsky.social @naturemedicine.bsky.social: 1) serious biomarker work from a pharma-sponsored trial👏👏 2) a tumor historically consid cold 🥶can respond to aPD1 🤩3) we need to redefine ER+ disease to enable personalized treatm✍️
Impressive paper on biomarkers for immunotherapy in RCC! Good to see biomarkers from pharma-sponsored clinical trials!
Our 1st translational paper in 2025 now in Nature Cancer —summary Figure attached
www.nature.com/articles/s43...
www.nature.com/articles/s43...
January 10, 2025 at 9:32 AM
Impressive paper on biomarkers for immunotherapy in RCC! Good to see biomarkers from pharma-sponsored clinical trials!
Interesting paper on neo-antigen specific T cell therapy! Congrats Cell Therapy team @nkinl.bsky.social
Just published: Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial
rdcu.be/d5ptS
rdcu.be/d5ptS
Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial
Nature Medicine - In this phase 1 trial of a personalized, neoantigen-specific autologous T cell therapy, BNT221, when given as monotherapy in patients with metastatic melanoma refractory to PD-1...
rdcu.be
January 3, 2025 at 10:29 PM
Interesting paper on neo-antigen specific T cell therapy! Congrats Cell Therapy team @nkinl.bsky.social
Reposted by Marleen Kok, MD PhD, NKI
Big fan of the concept of immunogenic cell death/inducing immunogenicity with 'conventional' therapies - so really looking forward to reading/hearing more about TONIC2 following the nice work from the original TONIC trial by @marleenkok.bsky.social & team @nkinl.bsky.social 👇
Exciting to present 🎤 new data #SABCS24 from TONIC2 study, follow-up from rdcu.be/d22kf. Do immune inductions using low dose dox or cisplatin indeed benefit pts? See us at P1-7-30 and during PS17-9 we show data on TME during acquired resistance to aPD1. With V. Geurts @nkinl.bsky.social @oncoalert
Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial
Nature Medicine - A pick-the-winner clinical trial design in patients with metastatic triple-negative breast cancer shows that immune induction with doxorubicin or cisplatin may improve clinical...
rdcu.be
December 11, 2024 at 10:39 AM
Big fan of the concept of immunogenic cell death/inducing immunogenicity with 'conventional' therapies - so really looking forward to reading/hearing more about TONIC2 following the nice work from the original TONIC trial by @marleenkok.bsky.social & team @nkinl.bsky.social 👇
Smart analyses approach in immunotherapy trials #SABCS24 with stellar 🤩 scientists @christinedesmedt.bsky.social @lambrechtslab.bsky.social C. Sotiriou, R. Ali and E. Romero
December 10, 2024 at 8:52 PM
Smart analyses approach in immunotherapy trials #SABCS24 with stellar 🤩 scientists @christinedesmedt.bsky.social @lambrechtslab.bsky.social C. Sotiriou, R. Ali and E. Romero